

## REMARKS

The Official Action of 29 October 2004 has been carefully considered and reconsideration of the application as amended is respectfully requested.

The claims have been amended to remove the bases for the rejections under 35 USC 112, first and second paragraphs appearing at paragraphs 5 and 6 of the Official Action. With particular respect to the rejections under 35 USC 112, second paragraph, claims 16 and 24 have been amended in the manner courteously suggested by the Examiner in paragraph 6a, and claims 13 and 15 have been amended in the manner courteously suggested by the Examiner in paragraphs 6c and 6d respectively. With respect to the rejection of claim 24 appearing at paragraph 6b, Applicants respectfully note that the Table on page 18 when read in conjunction with the specification at page 15, first full paragraph, makes clear that the recited single dose may reduce infectivity for seven or more days (e.g. 8 days). The recitation of “at least” is not indefinite merely because it is open-ended (see MPEP 2173.05(c)). All claims as amended are respectfully believed to be sufficiently definite to satisfy the dictates of 35 USC 112, second paragraph.

With respect to the rejections under 35 USC 112, first paragraph, it is respectfully submitted that the amendments to claims 11, 16 and 24 remove the bases for the rejections to these claims. The recitation in claim 11 that the amount of the claimed compound administered to the animal does not exceed 1.0 mg/kg of the body weight of the animal in a day is supported in the specification, for example, by the amounts of 1.0 mg/kg in Table IV on page 22 and 0.63 mg/kg in Table I on page 18.

The recitation that the animal is infected with a species of *Plasmodia* and that the compound is administered in an amount sufficient to reduce the infectivity of the animal is supported in the specification as filed at, for example, page 2, line 1; page 11, last paragraph; page 15, first and second full paragraphs and Table 1 on page 18. With particular respect to the rejection of claims 25, 31 and 32, Applicants respectfully traverse the rejection and call the Examiner's attention to the specification at page 2, line 1; page 11, last paragraph and page 15, first and second full paragraphs (e.g., "...the higher doses of 3.75 and 5.00 mg/kg rendered mature gametocytes non-infective to mosquitoes within 4-5 hours").


Claims 11-15 and 23 remain rejected as allegedly being unpatentable over the references cited at paragraph 4 of the Official Action. The Examiner maintained the rejection on the basis that the limitation of less than 1.25 mg/kg per day allegedly embraced the prior art dosage. Applicants respectfully disagree, but have now obviated this issue by amending the claimed dosage clearly to distinguish from the cited art.

In view of the above, it is respectfully submitted that all rejections and objections have been overcome and that the application is in allowable form. Nevertheless, Applicants would appreciate the opportunity to discuss this application with the Examiner before she acts further on it and, in a telephone discussion with the

undersigned on April 29, 2005, the Examiner courteously agreed to do this.

Accordingly, it is respectfully requested that the Examiner telephone the undersigned to set up a telephone interview at a time of her convenience.

Respectfully submitted,



---

CLIFFORD J. MASS  
LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NEW YORK 10023  
REG. NO.30,086(212)708-1890